comparemela.com

Latest Breaking News On - Pharma ltd nasdaq - Page 1 : comparemela.com

OKYO Pharma LTD: OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease

Monday, November 14th @ 8 am ET, registration details below NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) OKYO Pharma Ltd (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology bio-pharmaceutical

Tufts universityUnited statesTufts medical centerPedram hamrahGarys jacobTufts university school of medicinePharma ltd nasdaqKey opinion leaderPotential treatmentDry eyeTufts university schoolDry eye diseaseTranslational ocularSackler schoolGraduate biomedical sciencesOcular surface

Investegate |OKYO Pharma LTD Announcements | OKYO Pharma LTD: OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease

Investegate announcements from OKYO Pharma LTD, OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease

Tufts universityUnited statesUnited kingdomCity ofTufts medical centerPedram hamrahGarys jacobLondon stock exchangePharma limitedPharma ltd nasdaqTufts university school of medicinePotential treatmentDry eyeKey opinion leaderTufts university schoolDry eye disease

OKYO Pharma Hosting Key Opinion Leader Event Introducing

Monday, November 14th @ 8 am ET, registration details below NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) OKYO Pharma Ltd (Nasdaq: OKYO; LSE: OKYO).

Tufts universityUnited statesUnited kingdomCity ofTufts medical centerPedram hamrahGarys jacobLondon stock exchangePharma limitedPharma ltd nasdaqTufts university school of medicineKey opinion leaderPotential treatmentDry eyeTufts university schoolDry eye disease

vimarsana © 2020. All Rights Reserved.